- Trials with a EudraCT protocol (69)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
69 result(s) found for: Cancer genetics.
Displaying page 1 of 4.
EudraCT Number: 2014-003540-12 | Sponsor Protocol Number: NLG2101 | Start Date*: 2015-03-02 | |||||||||||
Sponsor Name:NewLink Genetics Corporation | |||||||||||||
Full Title: A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination with a Taxane Chemotherapy in Metastatic Breast Cancer | |||||||||||||
Medical condition: Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006323-31 | Sponsor Protocol Number: D1532C00016 | Start Date*: 2009-05-19 | |||||||||||||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||
Full Title: D1532C00016: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line... | |||||||||||||||||||||||
Medical condition: 2nd Line Patients with KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000155-41 | Sponsor Protocol Number: 1 | Start Date*: 2019-01-10 |
Sponsor Name:Department of Medical and Clinical Genetics, University of Helsinki | ||
Full Title: The effect of vitamin C on the gene methylation load in patients with TET2 mutations | ||
Medical condition: germline TET-2 gene mutation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001482-57 | Sponsor Protocol Number: SAKK_41/13-Aspirin | Start Date*: 2016-09-19 |
Sponsor Name:SAKK Swiss Group for Clinical Cancer Research | ||
Full Title: Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial | ||
Medical condition: PIK3CA mutated colon cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) HU (Prematurely Ended) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001946-17 | Sponsor Protocol Number: SGNLVA-005 | Start Date*: 2019-11-29 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | |||||||||||||
Medical condition: Multiple Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001238-21 | Sponsor Protocol Number: 2020-SESGEN | Start Date*: 2021-07-06 |
Sponsor Name:Institute of Health and Biomedical Research of Alicante | ||
Full Title: Gender biases in pain medicine: from omics to healthcare. | ||
Medical condition: The medical condition to be evaluated is the analgesic response of people with chronic low back pain who are going to be treated with opioids, guided by omics sciences (pharmacogenetics, epigeneti... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002678-34 | Sponsor Protocol Number: AMLSG30-18 | Start Date*: 2019-08-06 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics - AMLSG 30-18 | ||
Medical condition: Patients with newly diagnosed AML and intermediate- or adverse-risk genetics (according to 2017 ELN criteria), including AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML ac... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002289-35 | Sponsor Protocol Number: SGNLVA-002 | Start Date*: 2018-04-02 | |||||||||||||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||||||||||||
Full Title: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast C... | |||||||||||||||||||||||
Medical condition: Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002966-37 | Sponsor Protocol Number: 1-2018BSMO | Start Date*: 2019-01-23 |
Sponsor Name:Belgian Society of Medical Oncology | ||
Full Title: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. | ||
Medical condition: Advanced cancer patients that have a germline mutation or a somatic mutation in their tumor. Prostate and ovarian cancer patients and breast cancer patients who carry a BRCA1/2 mutation will be exc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002751-42 | Sponsor Protocol Number: SGN35-014 | Start Date*: 2013-02-18 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas | |||||||||||||
Medical condition: CD30-positive mature T-cell lymphomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) DE (Completed) ES (Completed) DK (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001671-51 | Sponsor Protocol Number: SGN35-023 | Start Date*: 2016-06-15 | ||||||||||||||||
Sponsor Name:Seattle Genetics, Inc. | ||||||||||||||||||
Full Title: A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF RITUXIMAB AND BENDAMUSTINE WITH OR WITHOUT BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY CD30-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA | ||||||||||||||||||
Medical condition: i) Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma ii) follicular non-Hodgkin lymphoma (NHL) grade 3b | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) CZ (Completed) FR (Completed) ES (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-005076-26 | Sponsor Protocol Number: SGNTV-001 | Start Date*: 2019-04-16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Seagen, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Disease in Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006459-10 | Sponsor Protocol Number: KU36-58 | Start Date*: 2007-07-18 | |||||||||||
Sponsor Name:KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies) | |||||||||||||
Full Title: A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associat... | |||||||||||||
Medical condition: Advanced ovarian cancer (stage IIIB/IIIC/IV) and confirmed BRCA+ status | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004860-12 | Sponsor Protocol Number: ERCAVATAR2015 | Start Date*: 2016-02-24 | |||||||||||
Sponsor Name:Centro Nacional Investigaciones Oncológicas (CNIO) | |||||||||||||
Full Title: Integrated Genomics and Avatar Mouse Models for Personalized Treatment of Pancreatic Cancer | |||||||||||||
Medical condition: Metastatic pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003479-78 | Sponsor Protocol Number: SGN22E-001 | Start Date*: 2018-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Seattle Genetics Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoin... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with locally advanced or metastatic urothelial cancer. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000540-60 | Sponsor Protocol Number: SGNTUC-017 | Start Date*: 2020-08-10 | ||||||||||||||||
Sponsor Name:Seattle Genetics, Inc. | ||||||||||||||||||
Full Title: MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer | ||||||||||||||||||
Medical condition: HER2+ Metastatic Colorectal Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) BE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003634-93 | Sponsor Protocol Number: NLG2107 | Start Date*: 2018-02-28 |
Sponsor Name:NewLink Genetics Corporation | ||
Full Title: A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo plus Pembrolizumab or Nivolumab in Adult Patients with Unresectable Stage III or Stage IV Malignant Mel... | ||
Medical condition: Adult Patients with Unresectable Stage III or Stage IV Malignant Melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000649-39 | Sponsor Protocol Number: EMR62202-502 | Start Date*: 2004-12-01 |
Sponsor Name:Merck KGaA | ||
Full Title: A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalat... | ||
Medical condition: Metastatic colorectal cancer refractory to irinotecan treatment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) AT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006458-91 | Sponsor Protocol Number: KU36-44 | Start Date*: 2007-05-22 | |||||||||||
Sponsor Name:KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies) | |||||||||||||
Full Title: A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associat... | |||||||||||||
Medical condition: Advanced breast cancer (stage IIIB/IIIC/IV) and confirmed BRCA+ status | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) ES (Ongoing) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001219-22 | Sponsor Protocol Number: SGNTV-002 | Start Date*: 2019-10-25 | |||||||||||||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||||||||||||
Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen | |||||||||||||||||||||||
Medical condition: Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
